# Relative Bioavailability Study of MELT-100, IV Midazolam, and IV Ketamine

> **NCT04767035** · PHASE1 · COMPLETED · sponsor: **Melt Pharmaceuticals** · enrollment: 25 (actual)

## Conditions studied

- Procedural Sedation

## Interventions

- **DRUG:** midazolam / ketamine sublingual tablet

## Key facts

- **NCT ID:** NCT04767035
- **Lead sponsor:** Melt Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-12-01
- **Primary completion:** 2021-01-14
- **Final completion:** 2021-01-14
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2021-02-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04767035

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04767035, "Relative Bioavailability Study of MELT-100, IV Midazolam, and IV Ketamine". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04767035. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*